Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

NCT03766763

Conditions: Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Chu Amiens Amiens, France

Chu Angers Angers, France

Ch Annecy Annecy, France

Ch Cote Basque Bayonne, France

View all 23 locations

View Trial Details

Active, not recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

NCT03734198

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations: Chu Amiens Sud Amiens, France

CH Annecy Genevois - Hématologie A3 Annecy, France

CHU Jean Minjoz - Hématologie Besançon, France

Hôpital Avicenne - Centre de Recherche Clinique Bobigny, France

View all 24 locations

View Trial Details

Active, not recruiting

Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

NCT07247383

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: 2ndAffiliated Hospital, School of Medicine, Zhejiang University, China Hangzhou, Zhejiang, China

View Trial Details

Active, not recruiting

A Multi-center Retrospective Study of INO Treating B-ALL

NCT07238907

Conditions: Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Hematologic Diseases, +12 more
Locations: Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai, Shanghai Municipality, China

View Trial Details

Active, not recruiting

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

NCT06581848

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Pfizer Seoul, South Korea

View Trial Details

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

NCT03233854

Conditions: B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, CD19 Positive, +22 more
Locations: Stanford University, School of Medicine Palo Alto, California, United States

View Trial Details

Active, not recruiting

Personalized Risk Stratification Model of Follicular Lymphoma Patients

NCT03436602

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: Arcispedale Santa Maria Nuova, AUSL IRCSS, Hematology Department Reggio Emilia, RE, Italy

Azienda Ospedaliera Universitaria Maggiore della Carità Novara, Italy

Institute of Oncology Research Bellinzona, Canton Ticino, Switzerland

Institute of Pathology Locarno, Canton Ticino, Switzerland

View Trial Details

Active, not recruiting

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

NCT02050347

Conditions: B-Cell ALL, B-Cell CLL, Burkitt Lymphoma, +21 more
Locations: Houston Methodist Hospital Houston, Texas, United States

Texas Children's Hospital Houston, Texas, United States

View Trial Details

Active, not recruiting

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT04060277

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +40 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, not recruiting

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT06521567

Conditions: Adenocarcinoma, Astrocytoma, Brain Diseases, +56 more
Locations: GSK Investigational Site Los Angeles, California, United States

GSK Investigational Site Iowa City, Iowa, United States

GSK Investigational Site Hackensack, New Jersey, United States

GSK Investigational Site Cincinnati, Ohio, United States

View all 20 locations

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions